<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940002</url>
  </required_header>
  <id_info>
    <org_study_id>17012</org_study_id>
    <secondary_id>2016-000962-47</secondary_id>
    <nct_id>NCT02940002</nct_id>
  </id_info>
  <brief_title>BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test</brief_title>
  <official_title>A 28-day, Double-blind, Randomized, Reference-controlled Psoriasis Plaque Test to Evaluate the Efficacy and Safety of Two Different BAY1003803 Formulation Types in 2 Concentrations Each in Treatment of Symptomatic Volunteers With Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy and safety of four BAY1003803 formulations by means of a within
      subject comparison in an open Psoriasis Plaque Test
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">March 17, 2017</completion_date>
  <primary_completion_date type="Actual">January 27, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in infiltrate thickness from day 1 to day 29 measured by sonography using 22 MHz B mode ultrasound</measure>
    <time_frame>Day 1 to 29</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>BAY1003803 0.1% lipophilic cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1003803 0.1% ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1003803 0.1% ointment (on plaque and healthy skin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1003803 0.01% lipophilic cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY1003803 0.01% ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAY1003803 0.01% ointment (on plaque and healthy skin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clobetasol propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betamethasone/calcipotriene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1003803</intervention_name>
    <description>Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect</description>
    <arm_group_label>BAY1003803 0.1% lipophilic cream</arm_group_label>
    <arm_group_label>BAY1003803 0.1% ointment</arm_group_label>
    <arm_group_label>BAY1003803 0.01% lipophilic cream</arm_group_label>
    <arm_group_label>BAY1003803 0.01% ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate</intervention_name>
    <description>Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect</description>
    <arm_group_label>Clobetasol propionate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone/calcipotriene</intervention_name>
    <description>Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect</description>
    <arm_group_label>Betamethasone/calcipotriene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female (non-childbearing potential) volunteer with stable plaque-type
             psoriasis, but otherwise healthy

          -  Age: 18-64 years

        Exclusion Criteria:

          -  Severe disease within the last 4 weeks prior to the first study drug administration as
             determined by the investigator

          -  Any topical antipsoriatics on plaques potentially to be treated in this trial
             (including corticosteroids, vitamin D analogues, immunomodulators, retinoids,
             dithranol and tar, except for salicylic acid (Pretreatment) in the 4 weeks before
             first treatment and/or planned during the trial, except for allowed topical treatment
             on the face, ears and scalp

          -  Systemic treatment depending on kind of treatment within 4 weeks and 6 months prior
             and/or planned during the trial

          -  Treatment with concomitant medication that may affect and provoke or aggravate
             psoriasis, e.g. antimalarial drugs, lithium, beta-blockers or
             angiotensin-converting-enzyme inhibitors (AEC inhibitors) unless on a stable dose for
             3 months before study medication initiation

          -  Clinico-chemical parameters of clinically significant deviation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque form psoriasis vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

